We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+21.79%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$569M
AUM Growth
+$158M
Cap. Flow
+$85.1M
Cap. Flow %
14.97%
Top 10 Hldgs %
57.69%
Holding
35
New
8
Increased
13
Reduced
–
Closed
4

Top Buys

Rank Stock Value
1
IBB icon
iShares Biotechnology ETF
IBB
+$10.5M
2
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$9.27M
3
ONC
BeOne Medicines Ltd
ONC
+$7.04M
4
ILMN icon
Illumina
ILMN
+$6.48M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$6.45M

Top Sells

Rank Stock Value
1
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$2.67M
2
GILD icon
Gilead Sciences
GILD
+$2.15M
3
OVID icon
Ovid Therapeutics
OVID
+$1.58M

Sector Composition

Rank Sector Weight
1 Healthcare 88.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NEOG icon
26
Neogen
NEOG
$2.59B
$4.35M 0.77%
+130,000
New +$3.92M
OSUR icon
27
OraSure Technologies
OSUR
$286M
$4.05M 0.71%
+240,000
New +$4.55M
CELG
28
CALL
DELISTED
Celgene Corp
CELG
$3.57M 0.63%
+40,000
New +$3.84M
ZLAB icon
29
Zai Lab
ZLAB
$2.05B
$2.88M 0.51%
+135,000
New +$3.06M
ADVM
30
DELISTED
Adverum Biotechnologies
ADVM
$1.74M 0.31%
+30,000
New +$1.87M
QTTB icon
31
Q32 Bio
QTTB
$450M
$1.12M 0.2%
+3,333
New +$1.12M
AGIO icon
32
CALL
Agios Pharmaceuticals
AGIO
$1.82B
– –
-25,000
Closed -$1.43M
GILD icon
33
Gilead Sciences
GILD
$163B
– –
-30,000
Closed -$2.15M
OVID icon
34
Ovid Therapeutics
OVID
$435M
– –
-160,000
Closed -$1.58M
SYRS
35
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
– –
-27,407
Closed -$2.67M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q1 2018 Portfolio in Review

As of Q1 2018, Casdin Capital held 35 positions worth $569M, up 38% from $411M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Casdin Capital deployed $85.1M of net new capital in Q1 2018, opening 8 new positions and adding to 13 existing holdings. Its largest new stake was iShares Biotechnology ETF: 95,000 shares worth $10.1M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 93% a quarter earlier.

On the sell side, the most notable exit was Syros Pharmaceuticals, Inc. Common Stock, an estimated $2.67M sold.

  • Casdin Capital's largest Q1 2018 buy was iShares Biotechnology ETF: 95,000 shares worth $10.1M.
  • Casdin Capital added most to Spark Therapeutics, Inc. Common Stock in Q1 2018, an estimated $9.27M increase.
  • Casdin Capital fully exited Syros Pharmaceuticals, Inc. Common Stock in Q1 2018, selling an estimated $2.67M.
  • Casdin Capital's ten largest holdings make up 58% of its $569M portfolio in Q1 2018.
  • Casdin Capital opened 8 new positions and closed 4 in Q1 2018.
  • Casdin Capital's portfolio value rose 38% quarter-over-quarter to $569M.

Based on Casdin Capital's 13F filing for Q1 2018, filed 15 May 2018.